Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis

TA254 Multiple sclerosis (relapsing-remitting) - fingolimod: review decision - July 2013 information

TA254 Multiple sclerosis (relapsing-remitting) - fingolimod: Appendix A - Decision paper presented to the Institute's Guidance Executive (PDF 391 KB)

TA254 Multiple sclerosis (relapsing-remitting) - fingolimod: review proposal - May 2013 information

TA254 Multiple sclerosis (relapsing-remitting) - fingolimod: Appendix A - provisional matrix of stakeholders (PDF 39 KB)

TA254 Multiple sclerosis (relapsing-remitting) - fingolimod: Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 750 KB)

TA254 Multiple sclerosis (relapsing-remitting) - fingolimod: press release information

Multiple sclerosis (relapsing-remitting) - fingolimod: EIA form (guidance development) (PDF 21 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: final appraisal determination information

Multiple sclerosis (relapsing-remitting) - fingolimod: final appraisal determination document (PDF 193 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 459 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: consultee and commentator comments on the ACD

Multiple sclerosis (relapsing-remitting) - fingolimod: Novartis (PDF 343 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Multiple Sclerosis Society (PDF 49 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Multiple Sclerosis Trust (PDF 322 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Association of British Neurologists (PDF 100 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Royal College of Nursing (PDF 21 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Department of Health (PDF 8.4 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: North Yorkshire and York PCT (PDF 64 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: NHS Centre for Reviews and Dissemination and Centre for Health Economics (PDF 49 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: expert comments on the ACD

Multiple sclerosis (relapsing-remitting) - fingolimod: Matthews (PDF 64 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Young (PDF 14 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: comments on the ACD received from the public through the NICE website (PDF 251 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Evidence Review Group discussion of manufacturer's reponse to second ACD (PDF 28 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod press release information

Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation 2

Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation document information

Multiple sclerosis (relapsing-remitting) - fingolimod: manufacturer's response to the appraisal consultation document

Multiple sclerosis (relapsing-remitting) - fingolimod: Novartis' response to the appraisal consultation document (PDF 488 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Patient Access Scheme submission (PDF 232 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: consultee and commentator comments on the appraisal consultation document

Multiple sclerosis (relapsing-remitting) - fingolimod: Multiple Sclerosis Society (PDF 69 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Multiple Sclerosis Trust (PDF 31 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Royal College of Nursing (PDF 15 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Royal College of Physicians (PDF 108 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Merck Serono (PDF 45 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Department of Health (PDF 9.2 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Young (PDF 14 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: web comments (PDF 284 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: other comments on the appraisal consultation document

Multiple sclerosis (relapsing-remitting) - fingolimod: comments sent by investigators at UK Trial Centres (PDF 29 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: comments sent by UK neurologists (PDF 282 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Catherine McKinnell MP (PDF 1.04 MB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Edward Milliband MP (PDF 266 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: Evidence Review Group critique of Novartis' response to the appraisal consultation document

Multiple sclerosis (relapsing-remitting) - fingolimod: response to manufacturer's comments on the ACD (PDF 32 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: response to manufacturer's PAS submission (PDF 48 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation

Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation document information

Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation - evaluation report

Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation - pre-meeting briefing (PDF 225 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation - Evidence Review Group report (PDF 1.53 MB)

Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation - factual accuracy check (PDF 113 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation - manufacturer submission

Manufacturer submission from Novartis (PDF 4.13 MB)

NICE request to the manufacturer for clarification on their submission (PDF 40 KB)

Manufacturer's response to NICE's request for clarification (PDF 470 KB)

Manufacturer response to Evidence Review Group request for an analysis of Population "1b but not 2" (PDF 41 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation - patient group, professional group and NHS organisation submission

Submission statement from the Multiple Sclerosis Society (PDF 1.05 MB)

Submission statement from the Multiple Sclerosis Trust (PDF 88 KB)

Submission statement from the Royal College of Nursing (PDF 70 KB)

Submission statement from NHS North Yorkshire and York PCT (PDF 56 KB)

Submission statement from South Staffordshire PCT (PDF 5.5 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: appraisal consultation - expert written personal statements

Expert written personal statement from Kinder (PDF 28 KB)

Expert written personal statement from Matthews (PDF 168 KB)

Expert written personal statement from Weir (PDF 25 KB)

Expert written personal statement from Young (PDF 112 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: final scope (PDF 53 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: final matrix (PDF 44 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: response to consultee and commentator comments on the draft scope (PDF 142 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: response to consultee and commentator comments on the matrix of consultees and commentators (PDF 49 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: draft scope (PDF 47 KB)

Multiple sclerosis (relapsing-remitting) - fingolimod: provisional matrix (PDF 31 KB)